Skip to content
2000
Volume 6, Issue 3
  • ISSN: 1872-2156
  • E-ISSN: 2212-3431

Abstract

The United States Supreme Court recently issued an opinion regarding the patentability of claims directed to diagnostic methods in Mayo Collab. Service v. Prometheus Lab., Inc. In this opinion, the Supreme Court held that correlations between metabolite levels in the human body and either therapeutic efficacy or adverse effects are unpatentable laws of nature. It further found that a patent claim to a method including such a correlation is unpatentable if the remainder of the claim contains only conventional and well-known steps. The Prometheus decision creates uncertainty regarding the scope of patentable subject matter, particularly in the fields of diagnostic and personalized medicine, that will remain until future cases apply this new doctrine.

Loading

Article metrics loading...

/content/journals/dnag/10.2174/187221512802717330
2012-12-01
2025-10-04
Loading full text...

Full text loading...

/content/journals/dnag/10.2174/187221512802717330
Loading

  • Article Type:
    Research Article
Keyword(s): Myriad; patentable; Patents; personalized medicine; Prometheus; unpatentable
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test